Aurora Spine (ASG) AI Stock Analysis

• Market Cap: C$21.07M
• Dividend Yield: N/A
• Average Volume (3M): 30.19K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.83
• Revenue Growth: 9.71%
• EPS Growth: -118.02%
• Country: CA
• Employees: 13
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Devices
• EPS (TTM): >-0.01
• Shares Outstanding: 78,054,950
• 10 Day Avg. Volume: 38,837
• 30 Day Avg. Volume: 30,190
• PEG Ratio: 0.46
• Price to Book (P/B): 4.78
• Price to Sales (P/S): 1.20
• P/FCF Ratio: 78.91
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 46 Neutral
• Price Target: C$0.27 ▼(-3.57% Downside)

Aurora Spine's overall stock score is primarily impacted by its financial performance challenges, including negative profitability and cash flow issues. Technical analysis shows a neutral trend, while valuation metrics are weak due to negative earnings and lack of dividends.

Positive Factors

Revenue Growth

The consistent revenue growth indicates a strong demand for Aurora Spine's products, suggesting effective market penetration and potential for future expansion.

Product Innovation

A focus on R&D and innovation in spinal implants and surgical solutions positions Aurora Spine as a leader in medical technology, potentially driving long-term competitive advantage.

Moderate Leverage

Moderate leverage indicates a balanced approach to financing, providing flexibility for future investments and growth opportunities without excessive risk.

Negative Factors

Profitability Challenges

Ongoing profitability issues highlight operational inefficiencies, which could hinder long-term financial stability and shareholder returns if not addressed.

Cash Flow Concerns

Negative cash flow growth indicates challenges in generating sufficient cash to support operations and growth, potentially limiting strategic flexibility.

Negative Return on Equity

A negative ROE suggests inefficient asset utilization, which could impact investor confidence and the company's ability to attract future capital.

Aurora Spine Business Overview & Revenue Model

Company Description

Aurora Spine (ASG) is a medical device company focused on developing innovative spinal implants and surgical solutions. The company operates in the orthopedic and spinal surgery sectors, providing a range of products that include interbody fusion devices, spinal fixation systems, and minimally invasive surgical tools. Aurora Spine aims to improve patient outcomes and enhance surgical efficiency through its advanced technology and commitment to research and development.

How the Company Makes Money

Aurora Spine generates revenue primarily through the sale of its spinal implants and surgical instruments to hospitals, surgical centers, and orthopedic surgeons. The company’s revenue model is based on direct sales and distribution agreements with medical facilities, where they supply their products for use in various spinal surgeries. Key revenue streams include the sale of interbody devices, fixation systems, and minimally invasive surgical tools. Additionally, Aurora Spine may benefit from partnerships with healthcare providers and collaboration with other medical technology firms, which can enhance its market reach and product offerings. The company also engages in research and development to innovate and expand its product line, potentially opening new revenue channels through patented technologies and advanced surgical solutions.

Aurora Spine Financial Statement Overview

Summary

Aurora Spine is experiencing revenue growth, but profitability and cash flow remain significant challenges. The company needs to address its operational inefficiencies and improve its cash flow management to enhance financial stability and shareholder value.

Income Statement

Aurora Spine's revenue has shown a positive growth trajectory with a 7.26% increase in the TTM period. However, the company is struggling with profitability, as evidenced by negative net profit and EBIT margins. The gross profit margin remains healthy at 54.67%, but the consistent negative net income and EBIT indicate operational challenges.

Balance Sheet

The company's debt-to-equity ratio of 0.62 in the TTM period suggests moderate leverage, which is an improvement from previous periods. However, the negative return on equity indicates that the company is not generating sufficient returns on shareholders' equity, pointing to potential inefficiencies in asset utilization.

Cash Flow

Aurora Spine's cash flow situation is concerning, with negative free cash flow growth and a low operating cash flow to net income ratio of 0.15 in the TTM period. The company needs to improve its cash generation capabilities to support its operations and growth.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	18.05M	17.56M	14.52M	14.88M	10.54M	8.65M
Gross Profit	10.78M	10.63M	8.21M	7.81M	4.83M	3.47M
EBITDA	-121.65K	179.90K	-446.20K	-469.27K	-1.55M	-573.86K
Net Income	-1.40M	-1.00M	-1.68M	-1.50M	-2.36M	-232.09K
Balance Sheet
Total Assets	16.26M	11.67M	11.99M	10.12M	10.56M	7.16M
Cash, Cash Equivalents and Short-Term Investments	926.33K	775.62K	766.83K	423.40K	3.17M	1.71M
Total Debt	3.30M	3.67M	3.65M	2.97M	2.55M	2.34M
Total Liabilities	7.86M	7.28M	6.69M	5.81M	4.99M	3.87M
Stockholders Equity	5.33M	4.40M	5.30M	4.32M	5.57M	3.28M
Cash Flow
Free Cash Flow	-59.98K	266.47K	-1.41M	-2.43M	-2.85M	-245.07K
Operating Cash Flow	673.38K	904.33K	-935.06K	-1.56M	-2.13M	309.57K
Investing Cash Flow	-486.99K	-484.32K	-479.13K	-873.21K	-720.61K	-554.64K
Financing Cash Flow	-369.08K	-361.22K	1.76M	-318.15K	4.31M	1.51M

Aurora Spine Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 0.28
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:ASG, the sentiment is Positive. The current price of 0.28 is above the 20-day moving average (MA) of 0.26, below the 50-day MA of 0.28, and below the 200-day MA of 0.30, indicating a neutral trend. The MACD of >-0.01 indicates Negative momentum. The RSI at 51.08 is Neutral, neither overbought nor oversold. The STOCH value of 77.78 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for TSE:ASG.

Aurora Spine Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
QIPT	70 Outperform	C$216.62M	-14.25	-10.51%	―	2.48%	-53.76%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
VPT	50 Neutral	C$22.64M	-5.65	―	―	28.59%	23.46%
ASG	46 Neutral	C$21.07M	-11.16	-31.12%	―	9.71%	-118.02%
PINK	46 Neutral	C$37.22M	-1.62	-181.70%	―	209.29%	35.38%
TLT	46 Neutral	C$62.98M	-16.29	-269.41%	―	1.46%	6.91%
PMED	46 Neutral	C$11.37M	-7.25	―	―	―	9.21%

Aurora Spine Corporate Events

Aurora Spine Bolsters IP Portfolio With Two New U.S. Patents

Aurora Spine has secured two new U.S. patents that broaden protection for its core implant platforms and deepen its technological differentiation in minimally invasive spine surgery. One patent, the tenth for the company’s flagship ZIP implant family, covers a spinal implant architecture that can be used for either motion preservation or fusion and is designed to distribute load more effectively than traditional rigid systems, enhancing the durability and clinical adaptability of this key revenue-driving platform. The second patent underpins Aurora’s DEXA Technology by formalizing a data-driven method of matching orthopedic implants to patient-specific bone density profiles, addressing a historically underutilized variable in spine surgery. Together, the newly issued patents strengthen Aurora Spine’s intellectual property portfolio, support future product development, and reinforce its positioning as an innovation-led player in the spinal implant market, with potential long-term benefits for surgeons, patients and shareholders.

The most recent analyst rating on (TSE:ASG) stock is a Hold with a C$0.27 price target. To see the full list of analyst forecasts on Aurora Spine stock, see the TSE:ASG Stock Forecast page.

Aurora Spine Reports Record Q3 2025 Results Amid Product Launches

Aurora Spine Corporation announced record financial results for the third quarter of 2025, marking a significant period of transition with the launch of two new product platforms, DEXA-L and Hydra ARO. Despite a slight decrease in total revenues compared to the previous year, the company achieved positive EBITDAC for the second consecutive quarter, reflecting efficient operations and market expansion. The introduction of new products is expected to act as growth catalysts, with initial sales already achieved, reinforcing Aurora Spine’s commitment to innovation and diversification in the spine and pain markets.

The most recent analyst rating on (TSE:ASG) stock is a Hold with a C$0.50 price target. To see the full list of analyst forecasts on Aurora Spine stock, see the TSE:ASG Stock Forecast page.

Aurora Spine to Showcase Innovations at NASS 2025

Aurora Spine Corporation announced its participation in the 2025 North American Spine Society Annual Meeting, where it will showcase its latest innovations at Booth #1622. The company will feature its newly launched Hydra Facet Fusion System and the DEXA-L device, part of its DEXA Technology Platform, which offers personalized spinal care through patient-matched implants. These advancements are expected to transform spinal surgery and enhance Aurora Spine’s industry positioning.

The most recent analyst rating on (TSE:ASG) stock is a Hold with a C$0.50 price target. To see the full list of analyst forecasts on Aurora Spine stock, see the TSE:ASG Stock Forecast page.

Aurora Spine Unveils Aurora Biologics to Enhance Spinal Fusion Success

Aurora Spine has launched Aurora Biologics, a new division aimed at enhancing spinal fusion success through innovative biologic solutions. This launch integrates seamlessly with Aurora’s existing spine ecosystem, offering a comprehensive platform that optimizes patient outcomes and surgical efficiency. The introduction of Aurora Biologics is expected to drive significant growth, with anticipated revenue increases and improved profit margins, positioning Aurora Spine as a leader in biologic performance in spine care.

The most recent analyst rating on (TSE:ASG) stock is a Hold with a C$0.50 price target. To see the full list of analyst forecasts on Aurora Spine stock, see the TSE:ASG Stock Forecast page.

Aurora Spine Proposes Extension of Warrant Expiry Date

Aurora Spine Corporation has announced a proposed extension of the expiry date for 6,445,939 common share purchase warrants to October 15, 2026, pending approval from the TSX Venture Exchange. This move is part of the company’s strategic efforts to enhance its financial flexibility and potentially strengthen its market position in the spine and interventional pain management industry.

The most recent analyst rating on (TSE:ASG) stock is a Hold with a C$0.50 price target. To see the full list of analyst forecasts on Aurora Spine stock, see the TSE:ASG Stock Forecast page.